Clinical Trials
67 trialsUsing Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Lumed
University Hospital, Basel, Switzerland
KinLET
ITM Solucin GmbH
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
National Cancer Institute (NCI)
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
LuPARP
Vastra Gotaland Region
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Legend Biotech USA Inc
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Eisai Inc.
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
NEUK203-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
F-Tryptophan PET/CT in Human Cancers
Barbara Ann Karmanos Cancer Institute
LANTana
Imperial College London
OXTEND-01
Debiopharm International SA
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens
Peking University Cancer Hospital & Institute
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET
Orano Med LLC
PRRT-PARPi
Erasmus Medical Center
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Harbour BioMed (Guangzhou) Co. Ltd.
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
Ascentage Pharma Group Inc.
Study of rSIFN-co for Patients With Advanced Solid Tumors
Sichuan Huiyang Life Science and Technology Corporation
PARLuNET
Peter MacCallum Cancer Centre, Australia
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Virogin Biotech Ltd.
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Molecular Targeting Technologies, Inc.
A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
Provectus Pharmaceuticals
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
University of Wisconsin, Madison
Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
Peking Union Medical College Hospital
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven
DUET-1
Xencor, Inc.
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Novartis
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Vanquish Oncology, Inc.
Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
PharmaMar
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
University of Kentucky